Green Cross Cell Immuncell-LC study out; Private placement pharma boom in China;

> Primary results from a Seoul National University Hospital pivotal study of Immuncell-LC, manufactured by South Korea's Green Cross Cell, were published in the journal Gastroenterology and showed adjuvant immunotherapy with activated cytokine-induced killer cells reduced recurrence and mortality rates by approximately 40% and 80%. Release

> Zhejiang Huahai Pharma told the Shanghai Stock Exchange it plans to raise as much as RMB307.9 million ($50.3 million) in a private placement to repay bank loans and boost working capital. Release (PDF) (Chinese)

> Tianjin Zhongxin Pharmaceutical received regulatory approval for a private placement, the company told the Shanghai Stock Exchange. Release (PDF) (Chinese)

> Chongqing Lummy Pharmaceutical said it would change its private placement plan and will now seek to raise RMB864 million ($139.27 million). Release (PDF) (Chinese)

> South Korea's Hanmi Pharmaceutical outlined a possible weekly insulin drug that combined "LAPSInsulin115" and "efpeglenatide" at the 75th American Diabetes Association Scientific Session on June 7. Release

> Takeda Pharmaceuticals said additional post-hoc analyses from a global study of alogliptin versus standard of care in patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome showed CV outcomes were not different for alogliptin compared with placebo in high CV risk patients with Type 2 diabetes on ACE inhibitors. Release

> China-based oncology biotech BeiGene has dosed the first patient in a Phase I study of BGB-A317 for the treatment of advanced cancer. Release (PDF)

> Health and Family Welfare Minister J.P. Nadda said India would amend the Drugs and Cosmetics Act to spur innovation and protect clinical trial participants. Report

> Taiwan's Academia Sinica research fellow Wu Han-chung said his team has a next-generation anticancer drug candidate that could greatly boost life expectancy for colorectal cancer patients by conjugating peptides with liposomes. Report

> Jazz Pharmaceuticals ($JAZZ) enrolled the first patients in a Phase III clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, with South Korea's SK Biopharmaceuticals part of the multi-center trials. Release

> The Institute of Pharmaceutical Sciences at the University of Graz, Austria, is researching ways to review choice or combinations of Western and Chinese medicine according to the patient's needs, according to Rudolf Bauer, head of the institute. Report

> Piramal Enterprises renamed the brand name of its ovulation test kits as "i-know" to comply with a court order to stop using the word "sure." Report

> Australia's Sun Biomedical said recently acquired Dimerix Bioscience received an Australian patent grant for combination kidney disease therapy. Release (PDF)